Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: Early experience and phase 1 results
Authors:
- A. Hayes‐JordanAHA. Hayes‐Jordan
- H. GreenHGH. Green
- 10 April 2012
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 59 (2) , 395-397
Abstract
Background: Intra‐abdominal metastasis is a rare form of tumor dissemination in children. Complete surgical resection is usually deemed impossible. Children are frequently offered palliative care only. We adopted an aggressive approach for these cases which includes removal of dozens to hundreds of tumor nodules followed by perfusion of the abdominal cavity with hyperthermic chemotherapy (HIPEC) with a curative intent.Methods: We evaluated toxicity in 23 children and young adults undergoing 27 HIPEC procedures using cisplatin. Disease diagnoses included rhabdomyosarcoma (RMS), non‐RMS soft tissue sarcoma, (NRSTS), desmoplastic small round cell tumor, (DSRCT), mesothelioma, Wilms tumor, melanomatosis, and adenocarcinoma. Patients underwent cytoreductive surgery followed by cisplatin at 40.5–41°C, for 90 minutes. A subset of these patients was enrolled on our phase 1 study and as part of dose escalation cohort received 150 mg/m2 of cisplatin. All toxicities were recorded.Results: Maximum tolerated dose was 100 mg/m2. Dose limiting toxicity was grade 3 renal failure. In five of 27, 18% had grade 3 or higher renal failure. One patient developed a subclinical decrease in hearing and there were 2 grade 3 hematologic toxicities, 2 grade 3 hepatic toxicities, and one grade 3 ileus. One patient suffered grade3 cardiotoxicity. There were no operative/perioperative mortalities. Surgical complications occurred in 5/27 (18%) of patients. With a follow‐up of 6–60 months, seven patients (26%) had no recurrence.Conclusions: HIPEC is reasonably tolerated in pediatric patients with extensive abdominal metastasis. More study is needed to determine for which histologies HIPEC is most efficacious. Pediatr Blood Cancer 2012;59:395–397.Keywords
This publication has 23 references indexed in Scilit:
- Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: State of the art and future developmentsSurgical Oncology, 2011
- Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Hyperthermic Intraperitoneal Chemotherapy Using a Closed Abdominal ProcedureThe Journal of Clinical Pharmacology, 2011
- Cytoreductive surgery associated to hyperthermic intraperitoneal chemoperfusion for desmoplastic round small cell tumor with peritoneal carcinomatosis in young patientsJournal of Pediatric Surgery, 2010
- Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with SarcomatosisAnnals of Surgical Oncology, 2007
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus StatementAnnals of Surgical Oncology, 2006
- Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma—A Prospective Study of 70 Consecutive CasesAnnals of Surgical Oncology, 2006
- Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal CarcinomaJournal of Clinical Oncology, 2006
- Peritoneal Surface Oncology: A progress reportEuropean Journal of Surgical Oncology, 2006
- Limited Survival in Patients With Carcinomatosis From Foregut Malignancies After Cytoreduction and Continuous Hyperthermic Peritoneal PerfusionJournal of Gastrointestinal Surgery, 2005
- Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinomaCancer, 1999